Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Miruna Sasu

Chief Strategy Officer, COTA, Inc.

As the Biden administration leans into the Cancer Moonshot 2.0, the life sciences industry has the opportunity to launch a new era of precision oncology. How can we accelerate progress toward truly personalized medicine and revolutionize cancer care?

Chief Strategy Officer, COTA, Inc.